Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Jing has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Jin

    Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China

    3 shared publications
  • An-An Liu

    Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China.

    2 shared publications
  • Bin Song

    Department of Pancreatic Surgery, Changhai Hospital of Shanghai, Naval Medical University, Shanghai, 200433, China

    2 shared publications
  • Bo Li

    Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Navy Military Medical University (Second Military Medical University), Shanghai, China

    2 shared publications
  • Gang Li

    Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Military Medical University (Second Military Medical University), Shanghai, China

    2 shared publications
  • Huan Wang

    Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Navy Military Medical University (Second Military Medical University), Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Integrated genomics and transcriptomics reveal key events in pancreatic neuroendocrine neoplasm

    by Shiwei Guo, Xiaohan Shi, Xiaoyi Yin, Suizhi Gao, Bo Li, Huan Wang, Yikai Li, Beilei Wang, Xiongfei Xu, Kailian Zheng, et al.

    Pancreatic neuroendocrine neoplasm (PanNEN) represents the second most common epithelial neoplasm of the pancreas, characterized by remarkable heterogeneit

  • Open Access

    Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors

    by Di Chen, Lei He, Liang Chen, Chen Ye, Fei Duan, Xiaofei Zhu, Wei Jing, Huojun Zhang, Wei Li

    Radiation-induced immunological and stromal changes in the pancreatic tumor microenvironment (TME) often develop adaptive radioresistance in clinical. Among these changes, cellular compensatory programmed cell death-ligand 1 (PD-L1) overexpression induced by radiation will promote the adaptive immune evasion, limiting the radiation-mediated antitumor effect. Regrettably, the PD-L1 overexpression will be further potentiated by transforming growth factor-β1 (TGF-β1) that abundantly secreted by irradiated pancreatic stellate cells. This further fosters an immunosuppressive TME, which constitutes one of the key factors contributing to the limited efficacy of combining radiotherapy with programmed cell death protein 1 (PD-1)/PD-L1 blockade in pancreatic ductal adenocarcinoma. To counteract this resistance mechanism, we developed a TME-responsive nanogel (pirfenidone@nanogel–hyaluronidase–anti-PD-L1 [PFD@NGHP]) for rescuing radiosensitization. The PFD@NGHP is composed of a reduction-sensitive core encapsulating pirfenidone and a cationic surface corona of hyaluronidase and anti-PD-L1 antibodies. At the intercellular level, PFD@NGHP effectively inhibited TGF-β1 secretion by about 50% and targeted PD-L1 for antibody-dependent cell-mediated cytotoxicity. In the 3-dimensional stromal microtumors, PFD@NGHP effectively penetrated in stroma (>400 μm in depth), suppressed pancreatic stellate cells, and potentiated radiosensitization. In murine models, PFD@NGHP ameliorated the stroma through TGF-β1 inhibition, subsequently increased T cell infiltration of about 30% CD8 + T cells, and amplified the efficacy of PD-L1 blockade. This effect synergized radiotherapy to sustain tumor regression and generate abscopal effects. Collectively, our study demonstrates that PFD@NGHP targets the TGF-β1–PD-L1 axis in a cascading manner, offering a promising clinical strategy to overcome the adaptive radioresistance of irradiated pancreatic ductal adenocarcinoma while providing a potential platform for translational nanomedicine evaluation.


  • Open Access

    A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma

    by Bo Li, Meilong Shi, Yang Wang, Penghao Li, Xiaoyi Yin, Guoxiao Zhang, Xiaochao Kang, Huan Wang, Suizhi Gao, Kailian Zheng, et al.


  • Open Access

    A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohort study

    by Bo Li, Beilei Wang, Pengjie Zhuang, Hongwei Cao, Shengyong Wu, Zhendong Tan, Suizhi Gao, Penghao Li, Wei Jing, Zhuo Shao, et al.

    Objective: To construct a novel tumor-node-morphology (TNMor) staging system derived from natural language processing (NLP) of pathology reports to predict outcomes of pancreatic ductal adenocarcinoma. Method: This retrospective study with 1657 participants was based on a large referral center and The Cancer Genome Atlas Program (TCGA) dataset. In the training cohort, NLP was used to extract and screen prognostic predictors from pathology reports to develop the TNMor system, which was further evaluated with the tumor-node-metastasis (TNM) system in the internal and external validation cohort, respectively. Main outcomes were evaluated by the log-rank test of Kaplan–Meier curves, the concordance index (C-index), and the area under the receiver operating curve (AUC). Results: The precision, recall, and F1 scores of the NLP model were 88.83, 89.89, and 89.21%, respectively. In Kaplan–Meier analysis, survival differences between stages in the TNMor system were more significant than that in the TNM system. In addition, our system provided an improved C-index (internal validation, 0.58 vs. 0.54, PPPP=0.017; 0.69 vs. 0.62, P=0.001; external validation: 0.69 vs. 0.65, P=0.098; 0.68 vs. 0.64, P=0.154; 0.64 vs. 0.55, P=0.032, respectively). Finally, our system was particularly beneficial for precise stratification of patients receiving adjuvant therapy, with an improved C-index (0.61 vs. 0.57, PPPP<0.001; respectively) compared with the TNM system. Conclusion: These findings suggest that the TNMor system performed better than the TNM system in predicting pancreatic ductal adenocarcinoma prognosis. It is a promising system to screen risk-adjusted strategies for precision medicine.


  • Open Access

    A Nanogel with Effective Blood-Brain Barrier Penetration Ability through Passive and Active Dual-Targeting Function

    by Jun Liu, Meng Li, Yong Huang, Li Zhang, Wei Li, Peng Cao, Weijie Min, Jingyuan Li, Wei Jing

    Clinically, surgery assisted by chemotherapy is the most effective treatment of cancer. But from our clinical observation, the median survival of patients with glioblastoma is still not so good with only 15-16 months. The low therapeutic index is mainly due to the blood-brain barrier (BBB) which significantly hindered the chemotherapeutic drug accumulation in tumor tissue. One main composition of the BBB is astrocyte, which contains a lipophilic cell membrane, which prevents more than 98 of small-molecule drugs from entering the brain. Previously, we found that the nanogel with passive targeting function can increase the BBB penetration ability, which indicates that it could be used to overcome the above mentioned in vivo obstacles which promoted drug accumulation in the tumor. In this study, thermosensitive targeted nanogel delivery systems (DPPC) with cell-penetrating peptides (CPP) are introduced onto the particle surface for active astrocyte breaking. The hydrodynamic radius of DPPC is around 300nm, the potential is about 0-5mV, and the TEM and DLS studies further confirm its well spherical morphology and uniform distribution. The DPPC is verified as the biocompatible carriers for further application by cell viability tests. The in vitro-constructed BBB model successfully proves that DPPC can efficiently penetrate the BBB, which is attributed to both the temperature-sensitive passive targeting and the active CPP penetration. Consequently, the intracellular doxorubicin (DOX) promotes such functional DPPC at the relatively high temperature inside tumor microenvironment (TME) (42C), which obviously improves intratumor drug accumulation and tumor cell-killing effects. The dual-targeted nanogel delivery systems designed in this study provides a more effective strategy for the treatment of glioma.


  • Open Access

    GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer

    by Yanzhe Liu, Lijuan Shao, Kuang Chen, Zizheng Wang, Jin Wang, Wei Jing, Minggen Hu

    Background: Growth differentiation factor (GDF) acted as a factor that regulated proliferation, apoptosis and differentiation in several tumors. However, the effects of growth differentiation factor (GDF11) in pancreatic cancer remain unclear. Purpose: To investigate the expression and significance of GDF11 in pancreatic cancer. Patients and methods: Pancreatic cancer and corresponding paracancerous tissues (n=28) were collected from the Department of Hepatobiliary and Pancreatic Surgical Oncology of Chinese PLA General Hospital. Tissue microarray was obtained from Outdo Biotech Co., Ltd. (Shanghai, People’s Republic of China). GDF11 mRNA and protein expressions in pancreatic cancer samples and cell lines were detected using qRT-PCR, Western-Blot and immunohistochemistry. Overexpression and knockdown of GDF11 were performed with lentiviral transduction system and siRNA technique in PANC-1 cell line and CFPAC-1 cell line. Proliferation, migration and invasion of pancreatic cancer cell lines were examinated by MTS and transwell assay, respectively. Flow cytometry was used for cell apoptosis analysis. Results: The results of this study indicated that GDF11 was significantly down-regulated in pancreatic cancer tissues compared with adjacent tissues of pancreatic cancer. GDF11 was also associated with low expression in pancreatic cancer cell lines when compared with normal pancreatic cell line. In a cohort of 63 pancreatic cancer patients, high GDF11 expression levels was associated with favorable perineural invasion, T classification, N classification and overall survival (OS). Cox proportional hazards model revealed that high GDF11 expression was an independent predictor of favorable prognosis (HR: 0.496; 95% CI: 0.255–0.967; P=0.040). Overexpression of GDF11 in PANC-1 cells repressed the proliferation, migration and invasion abilities in vitro. Inhibition of GDF11 in CFPAC-1 showed inverse results. Furthermore, enhanced GDF11 expression promoted apoptosis and down-regulated GDF11 expression inhibited apoptosis in pancreatic cancer cell lines. Conclusion: These findings suggested that GDF11 acted as a tumor suppressor gene for pancreatic cancer.


  • Open Access

    TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway

    by F Yin, G Sharen, F Yuan, Y Peng, R Chen, X Zhou, H Wei, B Li, W Jing, J Zhao

    Lipid reprogramming has been considered as a crucial characteristic in hepatocellular carcinoma (HCC) initiation and progression. However, detailed molecular mechanisms have yet to be clearly defined. Here, we examined the effects of tumor suppressor TIP30 on the regulation of HCC lipid metabolism. We found that decreased TIP30 expression leads to elevated fatty acid synthesis and enhanced levels of lipogenic enzymes SCD and FASN in HCC cells. Moreover, SREBP1 is one of the key transcription factors regulating liver lipid metabolism, and TIP30 deficiency significantly increased SREBP1 expression and nuclear accumulation. Small interfering RNAs targeting SREBP1 could reverse fatty acid synthesis induced by TIP30 deficiency. Furthermore, downregulating TIP30 activated the Akt/mTOR signaling pathway to upregulate SREBP1 expression, which promoted lipid metabolism by activating gene transcription of lipogenesis, including fasn and scd. We also showed that TIP30 deficiency-regulated lipid metabolism promoted proliferation of HCC cells. Clinically, our data revealed that TIP30 expression significantly correlated with SREBP1 in patients with HCC and that a combination of TIP30 and SREBP1 is a powerful predictor of HCC prognosis. Together, our data suggested a novel function of TIP30 in HCC progression and indicate that TIP30 regulation of SREBP1 may represent a novel target for HCC treatment.


  • Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells

    by Guoke Liu, Xiaoyu Fan, Min Tang, Rui Chen, Hao Wang, Rongjie Jia, Xuyu Zhou, Wei Jing, Huajing Wang, Yang Yang, et al.


  • Open Access

    Primary Uterine Peripheral T-cell Lymphoma

    by Jing Gong, Aisheng Dong, Yang Wang, Xuefeng Zhang, Panpan Yang, Li Wang, Wei Jing

    Primary uterine non-Hodgkin's lymphoma is extremely rare accounting for <1% of all extranodal non-Hodgkin's lymphomas. Imaging findings of primary uterine lymphoma have rarely been reported before. We present magnetic resonance imaging (MRI) and fluorine-18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/CT findings in a patient with primary uterine peripheral T-cell lymphoma.A 27-year-old female presented with intermittent fever with neutropenia for 7 months. MRI showed an ill-defined mass involved both the uterine corpus and cervix, resulting in diffuse enlargement of the uterus. This mass showed inhomogeneous hypointensity on unenhanced T1-weighted images, hyperintensity on diffusion-weighted imaging, relative hypointensity compared to the surrounding myometrium on T2-weighted images and lower enhancement than the surrounding myometrium on enhanced T1-weighted images. FDG PET/CT showed intense FDG uptake in the thickened wall of the uterine corpus and cervix with SUVmax of 26.9. There were multiple hypermetabolic lymph nodes in the pelvis and retroperitoneum. Uterine curettage and CT-guided biopsy of the uterine mass revealed peripheral T-cell lymphoma. Bone marrow biopsy revealed no evidence of lymphomatous involvement. The imaging and pathologic findings were consistent with primary uterine lymphoma. After 3 circles of chemotherapy, follow-up enhanced MRI showed decreased thickness of the uterine wall.Despite its rarity, primary uterine non-Hodgkin's lymphoma should be taken into consideration when a uterine tumor shows large size, relative hypointesity on both T2-weighted images and enhanced T1-weighted images compared to the surrounding myometrium, and intense FDG uptake on PET/CT. MRI may be helpful for describing the relationship between the tumor and adjacent structures. FDG PET/CT may be useful for tumor detection and staging.


  • Open Access

    Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation

    by Bin Song, Qi Bian, Yi-Jie Zhang, Cheng-Hao Shao, Gang Li, An-An Liu, Wei Jing, Rui Liu, Ying-Qi Zhou, Gang Jin, et al.

    Apoptosis-stimulating of p53 protein 2 (ASPP2) is one of the ASPP family members and it has been reported to be associated with human cancer. However, the role of it in pancreatic cancer is still not clear. We analyzed the expression level of ASPP2 in cancer tissue samples with RT-qPCR, Western Blotting assay and immunohistochemistry staining. We studied the biological function of ASPP2 and its mechanism with gene overexpression and gene silencing technologies. We determined the sensitivity of pancreatic cells with differential ASPP2 level to gemcitabine and whether autophagy inhibition affected the gemcitabine resistance, both in vitro and in vivo. Expression of ASPP2 was downregulated in cancerous tissues in comparison with para-cancerous tissues. ASPP2 expression was linked to clinical outcomes in patients and down-regulation of ASPP2 increased cell proliferation, autophagic flux, the activity of AMP Kinase of pancreatic cancer cells and vice versa. Knockdown of ASPP2 results in increased resistance to gemcitabine, which was attributed to the enhanced autophagy. ASSP2 expression is lower in cancerous tissues and decreased ASPP2 lead to higher cancer cells proliferation and autophagic flux, which contribute to the gemcitabine resistance.